Bicycle Therapeutics plc (BCYC) fair value analysis
Nasdaq · Updated 2026-10-19
BCYC price how computed
Valuation status
No fair-value estimate yetBCYC has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BCYC yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.46
- Sector
- Healthcare
- 12-month range
- $3.38–$8.76
- Market cap
- $242M
- From 52-week high
- -60.5%
- Shares outstanding
- 69.8M
- Rank in Healthcare by quality score
- #178 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company that develops therapeutic drugs based on bicycle chemistry, a proprietary platform technology designed to create stable, targeted molecules for treating diseases including oncology and other serious conditions. The company operates in the United States and the United Kingdom, conducting research and development activities to advance its pipeline of bicycle-based drug candidates toward clinical applications.
BCYC currently ranks #178 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $242M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $61.2M
- Net margin
- -311.1%
- EPS (TTM)
- $-2.73
- Gross margin
- 100.0%
- Debt / equity
- 0.03
- Revenue growth (3-yr avg)
- -29.4%
- Shares outstanding
- 69.8M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 43 · neutral
- 50-day average
- $3.91
- 200-day average
- $4.71
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-94.6%)
2026-03 ▼ miss (-29.9%)
2025-12 ▲ beat (+69.1%)
2025-09 ▲ beat (+20.6%)
2025-06 ▼ miss (-22.6%)
2025-03 ▼ miss (-3.5%)
2024-12 ▲ beat (+4.6%)
2024-09 ▲ beat (+7.7%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 6 buy · 3 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $9.5
- Target vs last price
- +174.6%
What our data shows for BCYC
- Shares are trading in the lower third of their 12-month price range of $3.38–$8.76.
- The 14-day relative strength index sits at a neutral 43.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BCYC's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BCYC conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BCYC stock undervalued?
TickrTrends has no fair-value estimate for BCYC yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BCYC's TickrTrends verdict?
BCYC is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BCYC compare to other Healthcare stocks?
BCYC ranks #178 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BCYC overbought or oversold?
BCYC's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BCYC report earnings next?
BCYC's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does BCYC usually beat earnings estimates?
Over its last 8 reported quarters BCYC beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BCYC?
Of 9 analysts covering BCYC, 6 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $9.5 (+174.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.